By Cyber Sense Billing Team · Published · Updated
The direct answer: approval must match the actual service
For molecular testing, verify whether the patient's payer requires authorization and whether the approved service matches the assay actually ordered and performed. Authorization is not a substitute for an appropriate order, medical necessity, accurate coding, or any applicable laboratory-specific requirements. Do not assume all molecular tests require authorization or that none do under Medicare. The answer depends on the program, product, jurisdiction, service, and current policy. Build a record connecting clinical intent, assay selection, supporting evidence, performing laboratory, authorization status when applicable, and the final claim. A generic approval note that cannot be linked to the performed service is weak operational evidence.
Document the clinical question and specific order
The ordering record should identify the intended testing and the clinical problem it is meant to address. Obtain relevant documentation through the established clinical records process rather than reconstructing the indication from a laboratory marketing description. CMS laboratory guidance emphasizes treating-provider intent and medical necessity. Molecular services can also raise questions about who may order additional testing in particular circumstances. Where a local contractor article applies, review its actual scope and associated manual references. Do not convert a jurisdiction-specific clarification into national permission for every laboratory to add testing. Clinical selection and any permitted additional-test decisions belong with appropriately authorized professionals.
Make authorization verification assay-specific
Record the payer product, authorization reference, approved service information, applicable dates, performing entity, and any stated conditions. Compare those details with the final assay configuration and proposed claim. If the assay changes after initial review, determine whether the authorization must be updated rather than assuming the earlier approval follows automatically. Distinguish authorization from laboratory registration, technical assessment, or identifier requirements that may apply under a particular program. None should be treated as interchangeable. Retain the payer response and the submitted clinical material so an analyst can identify what was actually reviewed and what remains unresolved before claim release.
Hypothetical scenario: the requested assay changes
A hypothetical oncology practice requests a molecular assay, and its staff obtain a plan authorization for the proposed service. During specimen review, the laboratory identifies that a different assay is being considered because of specimen characteristics. The billing team does not simply reuse the original authorization. It asks the clinical team to confirm the revised order and checks whether the payer's approval still applies to the changed service and performing laboratory. The record preserves both the original request and the subsequent decision. If the authorization or documentation remains unresolved, the team follows its escalation policy instead of representing the original approval as blanket coverage.
Use a molecular prebilling evidence checklist
A prebilling review should reconcile the ordered assay, performed service, final report, claim mapping, and applicable payer requirements. Identify gaps early enough that staff can request existing clinical evidence or resolve administrative mismatches without altering the medical record. Where the payer requires additional assay identifiers or specified documentation, verify those details against the controlling instructions. Avoid copying a successful submission from another patient as a universal template; indications and policies can differ. Maintain a visible exception owner for changed assays, missing authorizations, and incomplete records. Release decisions should cite the specific evidence, not merely say approved by billing.
- Verify the clinical order and documented indication.
- Match the performed assay to the final report.
- Confirm authorization requirements for the actual product.
- Review any applicable assay identifiers and claim instructions.
- Resolve differences between requested and performed services.
Respect local coverage and payer variation
Molecular testing policies can be highly specific. Review applicable national coverage provisions, local contractor policies, and commercial medical policies without treating one document as universal. The opened MolDX ordering clarification identifies its contractor jurisdictions; its relevance must be evaluated accordingly. Check effective dates and the policy version applicable to the service. Do not promise payment because a test is registered, assigned an identifier, authorized, or listed in a policy. Those facts address different requirements. If coverage remains uncertain, explain the uncertainty through the appropriate workflow and review patient-notice obligations for the actual payer rather than applying an Original Medicare form indiscriminately.
Keep clinical, authorization, and billing teams connected
Molecular billing problems often emerge when an assay changes without an equivalent update to the order, authorization, or claim configuration. Establish a formal notification path for those changes and require acknowledgment from the responsible teams. Review denials for mismatches among the requested service, approved service, and final claim rather than labeling every case authorization denied. Cyber Sense can help organize molecular laboratory documentation handoffs, authorization tracking, and billing exception queues. Request a consultation to evaluate how assay changes reach your revenue cycle team. Clinical appropriateness, interpretation of specialized coverage criteria, and legal compliance questions should remain with the qualified professionals responsible for those decisions.
Frequently asked questions
Does authorization guarantee payment for molecular testing?
No. The performed service must still satisfy applicable coverage, documentation, coding, enrollment, and claim requirements. Confirm the actual approval terms and investigate changes to the assay or performing laboratory.
Are MolDX instructions applicable to every laboratory payer?
No. Review the relevant contractor jurisdictions, policy scope, and service circumstances. Do not apply a local Medicare article as a universal commercial, Medicaid, or nationwide Medicare authorization rule.
Sources and further reading
Related pages
Need help with laboratory billing? See our Laboratory medical billing services.
Related articles
This article is general information, not legal or coding advice. Always check current CPT®, ICD-10-CM, CMS and payer guidance. Questions? Contact us.